Coronavirus Vaccine Study
US biotech company selected Paratus Clinical to be involved in a Phase 1/2 trial of a COVID-19 vaccine in healthy adults 18-59 years of age.
The ultimate goal of the Sponsor company was to allow rapid advancement during the current coronavirus pandemic.
- Paratus was the first Australian site activated and first to randomise a participant for Phase 2 trial.
- Site staff proved their flexibility and adaptability when Sponsor recruitment targets changed.
- 100% compliance to the study requirement of 24 hour data entry.
- Paratus Clinical's quality of participants, flexibility and speed contributed to the quick development of the vaccine.
“It would be hard to forget the work we did on a Phase 1/2 COVID-19 Vaccine Study investigating a Nanoparticle Vaccine directed against the SARS-CoV-2 Spike Protein. Being part of the global effort to find a safe and effective solution for the pandemic always gives a great sense of pride - especially in appreciating the level of collaboration and commitment our teams demonstrated. Always brings warmth whenever I reflect on the dedication that each and every member of the Clinical Trial Process, including the Trial Participants, contributed and should be proud to represent.”
DR JOSHUA KIM - Principal Investigator at Paratus Clinical, Central Coast
Phase II Flu Vaccine Study
Background:A UK-based biotech company working with an Australian CRO required fast recruitment for a Phase II flu vaccine study.
Requirement:Sponsor needed 2,200 healthy volunteers during the 2019 flu season.
- Paratus recruited 893 participants (more than double the initial target of 400)
- Timelines met for the study
- Paratus Western Sydney clinic was the highest recruiting site
Influenza Detection Diagnostic
Background:An Australian biotech had developed a new point-of-care diagnostic to detect influenza and needed access to patients with ‘influenza-like illnesses’ within 72 hours of symptom onset.
Solution:Paratus worked closely with partner GP practices to set up referral pathways for eligible and interested patients, as well as setting up inside a GP practice to accommodate the study.
- Paratus recruited over 150 patients
- The study was able to proceed with a statistically relevant number of patients
- Development of the diagnostic tool was able to continue
New Migraine Treatment
Background:A small Australian biotech developing a new migraine treatment had experienced difficulty in achieving successful patient recruitment
Requirement:Sponsor needed fast recruitment after experiencing previous delays.
- Paratus delivered 120% of target in two months
- The company was able to progress research to the next stage of development more rapidly than anticipated
Are you interested in participating in clinical trials?
We value your privacy and are committed to protecting your data and personal information.